Levodropropizine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Levodropropizine
Accession Number
DB12472
Description

Levodropropizine is under investigation in clinical trial NCT01573663 (A Drug-Drug Interaction Study of Ambroxol and Levodropropizine).

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 236.315
Monoisotopic: 236.152477892
Chemical Formula
C13H20N2O2
Synonyms
  • levodropropizina
  • Levodropropizine

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Categories

ATC Codes
R05DB27 — Levodropropizine
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazinanes
Sub Class
Piperazines
Direct Parent
Phenylpiperazines
Alternative Parents
N-arylpiperazines / Dialkylarylamines / Aniline and substituted anilines / N-alkylpiperazines / 1,3-aminoalcohols / Trialkylamines / Secondary alcohols / 1,2-diols / 1,2-aminoalcohols / Azacyclic compounds
show 3 more
Substituents
1,2-aminoalcohol / 1,2-diol / 1,3-aminoalcohol / Alcohol / Amine / Aniline or substituted anilines / Aromatic heteromonocyclic compound / Azacycle / Benzenoid / Dialkylarylamine
show 15 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
N-arylpiperazine, secondary alcohol, N-alkylpiperazine (CHEBI:82722)

Chemical Identifiers

UNII
3O31P6T4G3
CAS number
99291-25-5
InChI Key
PTVWPYVOOKLBCG-ZDUSSCGKSA-N
InChI
InChI=1S/C13H20N2O2/c16-11-13(17)10-14-6-8-15(9-7-14)12-4-2-1-3-5-12/h1-5,13,16-17H,6-11H2/t13-/m0/s1
IUPAC Name
(2S)-3-(4-phenylpiperazin-1-yl)propane-1,2-diol
SMILES
[H][[email protected]@](O)(CO)CN1CCN(CC1)C1=CC=CC=C1

References

General References
Not Available
PubChem Compound
65859
PubChem Substance
347828710
ChemSpider
59270
RxNav
52014
ChEBI
82722
ChEMBL
CHEMBL1288810
ZINC
ZINC000019594545
Wikipedia
Levodropropizine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentAcute Tracheobronchitis1
3CompletedTreatmentCoughing1
1CompletedTreatmentHealthy Volunteers1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
SolutionOral60 mg
SyrupOral0.6 g
Syrup600 mg/100mL
Syrup30 MG/5ML
Syrup2 mg/5ml
SyrupOral6 mg/mL
Tablet60 mg
Syrup60 mg/5ml
SyrupOral
SyrupOral600 mg
Solution / dropsOral60 MG/ML
SyrupOral30 MG/5ML
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility97.1 mg/mLALOGPS
logP0.63ALOGPS
logP0.61ChemAxon
logS-0.39ALOGPS
pKa (Strongest Acidic)14ChemAxon
pKa (Strongest Basic)7.65ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area46.94 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity68.79 m3·mol-1ChemAxon
Polarizability26.77 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on October 20, 2016 16:31 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates